CHF
MCID: CNG034
MIFTS: 69

Congestive Heart Failure (CHF)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Congestive Heart Failure

MalaCards integrated aliases for Congestive Heart Failure:

Name: Congestive Heart Failure 12 74 29 6 15 37 17 71 32
Heart Failure 43 71
Cardiac Failure Congestive 12
Congestive Heart Disease 12
Heart Failure Congestive 54
Weak Heart 12
Chf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6000
ICD9CM 34 428 428.0
MeSH 43 D006333
NCIt 49 C3080 C50577
SNOMED-CT 67 42343007 84114007
ICD10 32 I50 I50.0 I50.9
UMLS 71 C0018801 C0018802

Summaries for Congestive Heart Failure

Disease Ontology : 12 A heart disease that is characterized by any structural or functional cardiac disorder that impairs the ability of the heart to fill with or pump a sufficient amount of blood throughout the body.

MalaCards based summary : Congestive Heart Failure, also known as heart failure, is related to pulmonary edema and peripartum cardiomyopathy, and has symptoms including edema, tremor and chest pain. An important gene associated with Congestive Heart Failure is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Cardiac conduction and Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases. The drugs Amiloride and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include Adipose and Lateral Plate Mesoderm, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Heart failure (HF), also known as congestive heart failure (CHF) and congestive cardiac failure (CCF),... more...

Related Diseases for Congestive Heart Failure

Diseases related to Congestive Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1422)
# Related Disease Score Top Affiliating Genes
1 pulmonary edema 33.4 REN NPPB NPPA EDN1 AGTR1 ACE
2 peripartum cardiomyopathy 33.3 TTN MYH7 ADRB1 ACE
3 cardiac arrest 33.3 TTN REN NPPB MYH7 MYH6 ACE
4 orthostatic intolerance 33.3 REN EDN1 AGTR1 ADRB1 ADRA2C ACE
5 hypertensive heart disease 32.9 REN NPPB NPPA AGTR1 ACE
6 twin-to-twin transfusion syndrome 32.5 REN NPPA AGTR1
7 heart disease 32.5 TTN REN NPPC NPPB NPPA MYH7
8 mitral valve insufficiency 32.4 REN NPPB NPPA MYH6 ACE
9 sleep apnea 32.3 REN NPPB EDN1 ACE
10 atrial standstill 1 32.2 TTN NPPB NPPA MYH7 MYH6 CRYAB
11 central sleep apnea 32.2 REN NPPB NPPA ACE
12 left bundle branch hemiblock 32.1 REN NPPB ACE
13 heart valve disease 32.1 REN NPPB NPPA MYH6 ACE
14 tricuspid valve insufficiency 32.1 REN NPPB EDN1 ACE
15 angina pectoris 32.0 NPPB EDN1 ADRB1 ACE
16 arteries, anomalies of 32.0 REN EDN1 AGTR1 ACE
17 cardiogenic shock 32.0 NPPB ADM
18 systolic heart failure 32.0 TTN NPPB NPPA EDN1 ADRB1 ACE
19 mitral valve disease 31.9 REN NPPB NPPA AGTR1 ACE
20 atrial fibrillation 31.9 TTN REN NPPB NPPA MYH7 CACNA1C
21 mitral valve stenosis 31.9 REN NPPB NPPA ACE
22 aortic valve insufficiency 31.9 REN NPPB ACE
23 lipoprotein quantitative trait locus 31.9 REN NPPB NPPA MYH6 EDN1 AGTR1
24 pure autonomic failure 31.8 REN NPPA ACE
25 pericardial effusion 31.8 REN NPPB NPPA ACE
26 diastolic heart failure 31.7 TTN REN NPPB NPPA AGTR1 ACE
27 pulmonary hypertension 31.7 REN NPPC NPPB NPPA EDN1 AGTR1
28 vascular disease 31.7 REN NPPB EDN1 AGTR1 ACE
29 kidney disease 31.7 REN NPPC NPPB NPPA EDN1 AGTR1
30 syncope 31.7 TTN NPPA ACTN2
31 pulmonary embolism 31.7 NPPB NPPA ACE
32 atrioventricular block 31.6 TTN NPPB MYH7 CRYAB CACNA1C ACE
33 dilated cardiomyopathy 31.6 VCL TTN REN NPPC NPPB NPPA
34 patent ductus arteriosus 1 31.5 REN NPPB MYH6 EDN1 ACE
35 chronic kidney disease 31.5 REN NPPC NPPB NPPA EDN1 AGTR1
36 right bundle branch block 31.5 NPPB CACNA1C ACE
37 constrictive pericarditis 31.5 TTN NPPB ACE
38 atrial heart septal defect 31.5 TTN NPPB NPPA MYH7 MYH6 EDN1
39 respiratory failure 31.5 TTN REN NPPB NPPA MYH7 EDN1
40 chagas disease 31.5 NPPB ADRB1 ACE
41 alcoholic cardiomyopathy 31.4 TTN REN ACE
42 sick sinus syndrome 31.4 TTN NPPA MYH6 CACNA1C
43 sleep disorder 31.4 REN EDN1 ACE
44 anterolateral myocardial infarction 31.4 NPPB NPPA ACE
45 sexual disorder 31.3 EDN1 ADRA2C ACE
46 muscular dystrophy 31.3 VCL TTN MYH7 CRYAB AGTR1 ACTN2
47 hypertrophic cardiomyopathy 31.3 VCL TTN REN NPPB NPPA MYH7
48 aortic valve disease 2 31.3 TTN REN NPPB NPPA MYH7 MYH6
49 restrictive cardiomyopathy 31.3 TTN NPPB MYH7 MYH6 CRYAB CACNA1C
50 aortic valve disease 1 31.3 REN MYH6 EDN1 AGTR1 ACE

Graphical network of the top 20 diseases related to Congestive Heart Failure:



Diseases related to Congestive Heart Failure

Symptoms & Phenotypes for Congestive Heart Failure

UMLS symptoms related to Congestive Heart Failure:


edema, tremor, chest pain, angina pectoris, syncope, equilibration disorder

MGI Mouse Phenotypes related to Congestive Heart Failure:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ACE ADM ADRA2C ADRB1 AGTR1 CACNA1C
2 homeostasis/metabolism MP:0005376 10 ACE ADM ADRA2C ADRB1 AGTR1 CACNA1C
3 mortality/aging MP:0010768 9.77 ACE ADM ADRA2C ADRB1 AGTR1 CACNA1C
4 muscle MP:0005369 9.36 ADM ADRB1 CACNA1C CRYAB EDN1 MYH6

Drugs & Therapeutics for Congestive Heart Failure

Drugs for Congestive Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 954)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Etanercept Approved, Investigational Phase 4 185243-69-0
4
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
5
Insulin lispro Approved Phase 4 133107-64-9
6
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
7
Deferiprone Approved Phase 4 30652-11-0 2972
8
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
9
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
10
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
11 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
12
Zopiclone Approved Phase 4 43200-80-2 5735
13
Tirofiban Approved Phase 4 144494-65-5 60947
14
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
15
Pancrelipase Approved, Investigational Phase 4 53608-75-6
16
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
17
Cefazolin Approved Phase 4 25953-19-9 656510 33255
18
Arsenic trioxide Approved, Investigational Phase 4 1327-53-3 518740
19
Glyburide Approved Phase 4 10238-21-8 3488
20
Pantoprazole Approved Phase 4 102625-70-7 4679
21
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
22
Ramipril Approved Phase 4 87333-19-5 5362129
23
Linagliptin Approved Phase 4 668270-12-0 10096344
24
Alogliptin Approved Phase 4 850649-61-5 11450633
25
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
26
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
27
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
28
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
29
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
30
Fenofibrate Approved Phase 4 49562-28-9 3339
31
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
32
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
33
Manidipine Approved, Investigational Phase 4 89226-50-6
34
Desflurane Approved Phase 4 57041-67-5 42113
35
Magnesium citrate Approved Phase 4 3344-18-1
36 Apricot Approved Phase 4
37
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
38
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
39
Ibuprofen Approved Phase 4 15687-27-1 3672
40
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
41
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
42
Trandolapril Approved Phase 4 87679-37-6 5484727
43
Magnesium oxide Approved Phase 4 1309-48-4 14792
44
Terbutaline Approved Phase 4 23031-25-6 5403
45
Ledipasvir Approved Phase 4 1256388-51-8 67505836
46
Clevidipine Approved, Investigational Phase 4 167221-71-8
47
Dipyridamole Approved Phase 4 58-32-2 3108
48
Clozapine Approved Phase 4 5786-21-0 2818
49
Haloperidol Approved Phase 4 52-86-8 3559
50
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795

Interventional clinical trials:

(show top 50) (show all 6892)
# Name Status NCT ID Phase Drugs
1 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
2 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
3 Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF) Unknown status NCT00409916 Phase 4
4 Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
5 Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
6 A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart Unknown status NCT00326690 Phase 4
7 Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins Unknown status NCT02797340 Phase 4 Metformin
8 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
9 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
10 Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project) Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
11 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
12 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
13 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
14 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
15 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
16 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
17 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
18 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
19 Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study Unknown status NCT00601679 Phase 4
20 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
21 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
22 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
23 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
24 Pre-hYpertension tReament With A coMbinatIon of Dietary Supplements and Life-style Modifications Unknown status NCT01682291 Phase 4
25 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
26 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
27 Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
28 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
29 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
30 Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Unknown status NCT03574857 Phase 4 Metolazone Oral Tablet;Chlorothiazide Injection
31 Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy Unknown status NCT03380520 Phase 4 Ferric Carboxymaltose;Placebo
32 A Pilot Feasibility Study in Recovered Heart Failure Unknown status NCT02859311 Phase 4 Withdrawal of therapy
33 Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial Unknown status NCT03096613 Phase 4 Levothyroxine
34 Double-blind Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of Intermittent, Long-term Administration of Levosimendan in Patients With Advanced Heart Failure Unknown status NCT00988806 Phase 4 Levosimendan;Placebo
35 Comparison of High-dose Furosemide Versus the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure Unknown status NCT00937092 Phase 4 Furosemide;low-dose dopamine + low-dose furosemide
36 The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial Unknown status NCT01942109 Phase 4 Furosemide;Torasemide
37 Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients Unknown status NCT02546856 Phase 4
38 Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence Unknown status NCT01016431 Phase 4
39 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
40 Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH) Unknown status NCT03437369 Phase 4 Ivabradine Oral Tablet
41 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
42 A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects. Unknown status NCT00885651 Phase 4 Metoprolole (Selo-Zok ®);Placebo
43 Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor Unknown status NCT01156207 Phase 4 Aliskiren
44 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
45 Assessment of Clinical Effect and Treatment Quality of Rapid Release Carvedilol Versus SLOW Release Carvedilol-SR in HEART FAILURE Patient (SLOW-HF): A Prospective Randomized, Open-label, Multicenter Study Unknown status NCT03209180 Phase 4 CarVeDilol-SR (Slow Release);Carvedilol IR (Immediate Release)
46 Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function Unknown status NCT00418119 Phase 4 erythropoietin
47 Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis Unknown status NCT02754518 Phase 4 Entresto
48 Latin America Cardiac Resynchronization Therapy Study Unknown status NCT01238874 Phase 4
49 Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy Unknown status NCT02166060 Phase 4 Ivabradine
50 Randomized-Controlled-Double Blind Trial of Low Dose Dobutamine in Advanced Heart Failure Patients in a Day-Care Clinic Unknown status NCT01930734 Phase 4 Dobutamine;Normal Saline

Search NIH Clinical Center for Congestive Heart Failure

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Atenolol
benazepril
Benazepril hydrochloride
Bendroflumethiazide
benzthiazide
Bisoprolol
Bisoprolol Fumarate
Bumetanide
candesartan
candesartan cilexetil
Captopril
carvedilol
carvedilol phosphate
Chlorothiazide
Chlorothiazide sodium
Chlorthalidone
coenzyme Q10
cyclothiazide
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
esmolol
Esmolol hydrochloride
Ethacrynate Sodium
Ethacrynic Acid
Fenoldopam
Fenoldopam Mesylate
Fosinopril
Fosinopril Sodium
Furosemide
Growth Hormone
Hydralazine
Hydralazine Hydrochloride
Hydrochlorothiazide
Hydroflumethiazide
Inamrinone
inamrinone lactate
Indapamide
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Labetalol
Labetalol hydrochloride
Lisinopril
Losartan
Losartan Potassium
Methyclothiazide
Metolazone
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Milrinone
Milrinone Lactate
moexipril
Moexipril hydrochloride
Nadolol
Nitroglycerin
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
Polythiazide
Propranolol
Propranolol Hydrochloride
quinapril
Quinapril hydrochloride
quinethazone
Ramipril
Sodium Nitroprusside
somatrem
Somatropin
SOMATROPIN (RECOMBINANT DNA ORIGIN)
Spironolactone
SPIRONOLACTONE PWDR
telmisartan
Timolol
Timolol Hemihydrate
Timolol Maleate
torsemide
trandolapril
Trichlormethiazide
valsartan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Congestive Heart Failure cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Congestive Heart Failure:
ACP-01, autologous angiogenic precursor cells for cardiac diseases
Adipose-derived stem cells for treatment of congestive heart failure
BMAC, autologous bone marrow aspirate concentrate for congestive heart failure
Bone marrow-derived adult mononuclear cells for heart diseases
Cardiac progenitor cells for single-ventricle anomalies
Cardiosphere-derived autologous stem cells for reverse ventricular dysfunction
C-Cure, mesenchymal stem cell-derived cardiomyocytes for heart failure
CD133+ bone marrow-derived stem cells in conjuction with coronary artery bypass grafting
CD34+ stem cells for treatment of congestive heart failure
Enriched bone marrow-derived progenitor cells for heart diseases
ERCs, endometrial regenerative cells for congestive heart failure
Human cardiac-derived stem cell for the treatment of congestive heart failure
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesenchymal precursor cells for cardiovascular diseases
MyoCell, muscle stem cells for severe heart damage
Peripheral or bone marrow-derived stem cells for chronic heart failure
Embryonic/Adult Cultured Cells Related to Congestive Heart Failure:
Angiogenic cell precursors
Adipose-derived mesenchymal stem cells (family)
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 18351022 23788089 15995108
Bone marrow-derived mononuclear cells PMIDs: 20524773 20445812 19699857 22137069
Cardiac stem cells PMIDs: 17502484 14530411 18754813
Cardiac progenitor cells PMIDs: 17502484 14530411 18754813
Cardiosphere-derived cells PMIDs: 22336189
Cardiomyocyte-like cells PMIDs: 18835562 23583247
Bone marrow-derived CD133+ cells PMIDs: 17320570
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22163120
Bone marrow-derived progenitor cells PMIDs: 16990385 22651868 16990384 18794392 22936827 23362308
Endometrial regenerative cells PMIDs: 18005405 23510656 20398245 19232091
Human cardiac stem cells PMIDs: 17502484 19038683 17150190
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 20850099 21155976
Skeletal myoblasts (MyoCell) PMIDs: 19051139 15615560 16446778
Bone marrow-derived mononuclear cells PMIDs: 20668107 19761394 22834565 21596713

Cochrane evidence based reviews: heart failure

Genetic Tests for Congestive Heart Failure

Genetic tests related to Congestive Heart Failure:

# Genetic test Affiliating Genes
1 Congestive Heart Failure 29

Anatomical Context for Congestive Heart Failure

MalaCards organs/tissues related to Congestive Heart Failure:

40
Heart, Kidney, Testes, Lung, Endothelial, Breast, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Congestive Heart Failure:
# Tissue Anatomical CompartmentCell Relevance
1 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
2 Lateral Plate Mesoderm Splanchnic Mesoderm Pericytes Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Congestive Heart Failure

Articles related to Congestive Heart Failure:

(show top 50) (show all 55999)
# Title Authors PMID Year
1
Effects of eythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patients. 61 54
18760492 2010
2
Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol. 61 54
20128603 2010
3
Provider adherence to clinical guidelines related to lipid-lowering medications. 61 54
20180482 2010
4
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. 61 54
19763821 2010
5
Alterations in plasma semicarbazide-sensitive amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction. 61 54
20391898 2010
6
Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain. 61 54
19666591 2009
7
Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. 54 61
19560695 2009
8
A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. 61 54
19327624 2009
9
The clinical pharmacology of eplerenone. 54 61
19379127 2009
10
Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. 54 61
19269262 2009
11
[The cardiorenal syndrome and optimal treatment of renal anemia]. 61 54
19370853 2009
12
Brain natriuretic peptide (BNP) level is closely related to the extent of left ventricular sympathetic overactivity in chronic ischemic heart failure. 54 61
19293536 2009
13
Porous silicon affinity chips for biomarker detection by MALDI-TOF-MS. 61 54
18948066 2008
14
Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. 54 61
17662495 2008
15
[Serum levels of fatty acid-binding protein and brain natriuretic peptide in children with pneumonia complicated by acute congestive heart failure]. 61 54
18554454 2008
16
Effect of erythropoietin in a patient with severe congestive heart failure--a case report. 54 61
18756924 2008
17
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. 54 61
18458262 2008
18
Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure. 61 54
19804290 2008
19
B-type natriuretic peptide: a biomarker for the diagnosis and risk stratification of patients with septic shock. 54 61
18347270 2008
20
Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. 54 61
18446719 2008
21
Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. 54 61
18219303 2008
22
Accuracy of the isovolumic relaxation time in the emergency diagnosis of new-onset congestive heart failure with preserved left ventricular systolic function in the setting of B-type natriuretic peptide levels in the mid-range. 61 54
17395301 2008
23
A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. 61 54
18021271 2008
24
[The role of urotensin II in human pathophysiology]. 61 54
19323069 2008
25
The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction. 54 61
19128227 2008
26
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. 61 54
18953278 2008
27
Clinical correlates of very high brain natriuretic peptide levels in hospitalized patients. 54 61
18256556 2008
28
Low plasma levels of brain natriuretic peptide in severe acute heart failure: merely a case? 61 54
17382416 2007
29
Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure. 54 61
17967592 2007
30
The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. 61 54
17923351 2007
31
Aldosterone and end-organ damage. 61 54
17683282 2007
32
ANP is cleared much faster than BNP in patients with congestive heart failure. 61 54
17479256 2007
33
The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure. A study on 686 consecutive patients. 61 54
17452135 2007
34
Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. 54 61
17223209 2007
35
Cut-off values of B-type natriuretic peptide for the diagnosis of congestive heart failure in patients with dyspnoea visiting emergency departments: a study on Korean patients visiting emergency departments. 61 54
17452702 2007
36
Usefulness of bedside tissue Doppler echocardiography and B-type natriuretic peptide (BNP) in differentiating congestive heart failure from noncardiac cause of acute dyspnea in elderly patients with a normal left ventricular ejection fraction and permanent, nonvalvular atrial fibrillation: insights from a prospective, monocenter study. 54 61
17456069 2007
37
Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. 61 54
17361123 2007
38
AMPD1 gene polymorphism and survival in patients with stable congestive heart failure. 61 54
17452134 2007
39
Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. 54 61
17083971 2007
40
Plasma levels of adrenomedullin and atrial natriuretic peptide in patients with congestive heart failure of various etiologies. 54 61
17511350 2007
41
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 54 61
17345160 2007
42
Discovery of new cardiovascular hormones for the treatment of congestive heart failure. 54 61
17346128 2007
43
Analytical and clinical performance of three natriuretic peptide tests in the emergency room. 61 54
17484634 2007
44
[Genetic polymorphism of beta-adrenergic receptors and mortality in ischemic heart disease]. 54 61
17374341 2007
45
Aquaporins as targets for drug discovery. 54 61
17692010 2007
46
Gene polymorphism of angiotensin-converting enzyme and angiotensin II type 1 receptor in patients with congestive heart failure. 54 61
18767410 2007
47
Brain natriuretic peptide--the biological marker in the diagnosis of overt congestive heart failure and myocardial ischemia. 54 61
17694799 2007
48
Brain natriuretic peptide plasma level is a reliable indicator of advanced diastolic dysfunction in patients with chronic heart failure. 61 54
16476572 2007
49
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. 61 54
16870827 2007
50
[Plasma urotensin II level in patients with chronic congestive heart failure]. 61 54
18634521 2006

Variations for Congestive Heart Failure

ClinVar genetic disease variations for Congestive Heart Failure:

6 (show all 18) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ABCC8 NM_000352.6(ABCC8):c.3517G>A (p.Val1173Met)SNV Likely pathogenic 35609 rs141322087 11:17426099-17426099 11:17404552-17404552
2 ABCC8 NM_000352.6(ABCC8):c.1793G>A (p.Arg598Gln)SNV Likely pathogenic 523361 rs1344172059 11:17452385-17452385 11:17430838-17430838
3 ANK2 NM_001148.6(ANK2):c.10693G>A (p.Glu3565Lys)SNV Conflicting interpretations of pathogenicity 190573 rs786205727 4:114281990-114281990 4:113360834-113360834
4 MYH6 NM_002471.3(MYH6):c.3988G>A (p.Ala1330Thr)SNV Conflicting interpretations of pathogenicity 191714 rs757840030 14:23858255-23858255 14:23389046-23389046
5 CRYAB NM_001289808.2(CRYAB):c.460G>A (p.Gly154Ser)SNV Conflicting interpretations of pathogenicity 41926 rs150516929 11:111779556-111779556 11:111908832-111908832
6 TTN NM_001267550.2(TTN):c.63023C>T (p.Thr21008Ile)SNV Conflicting interpretations of pathogenicity 47188 rs72646850 2:179453429-179453429 2:178588702-178588702
7 TTN NM_001267550.2(TTN):c.69130C>T (p.Pro23044Ser)SNV Conflicting interpretations of pathogenicity 47265 rs55980498 2:179441932-179441932 2:178577205-178577205
8 TTN NM_001267550.2(TTN):c.84923A>C (p.Gln28308Pro)SNV Conflicting interpretations of pathogenicity 47441 rs201674674 2:179425936-179425936 2:178561209-178561209
9 TTN NM_001267550.2(TTN):c.8902+14T>ASNV Conflicting interpretations of pathogenicity 137827 rs13388274 2:179634392-179634392 2:178769665-178769665
10 CACNA1C NM_000719.7(CACNA1C):c.3049-10C>TSNV Conflicting interpretations of pathogenicity 166769 rs186741807 12:2714835-2714835 12:2605669-2605669
11 EYA4 NM_004100.5(EYA4):c.347C>T (p.Ala116Val)SNV Conflicting interpretations of pathogenicity 355443 rs747223436 6:133777763-133777763 6:133456625-133456625
12 PRKAG2 NM_016203.4(PRKAG2):c.431C>T (p.Pro144Leu)SNV Uncertain significance 181485 rs150140412 7:151478273-151478273 7:151781187-151781187
13 RYR2 NM_001035.3(RYR2):c.10640C>T (p.Thr3547Met)SNV Uncertain significance 201305 rs552050895 1:237886513-237886513 1:237723213-237723213
14 VCL NM_014000.3(VCL):c.1490T>C (p.Ile497Thr)SNV Uncertain significance 505024 rs572757800 10:75854166-75854166 10:74094408-74094408
15 ACTN2 NM_001103.3(ACTN2):c.1727T>C (p.Met576Thr)SNV Likely benign 691721 1:236914840-236914840 1:236751540-236751540
16 TTN NM_001267550.2(TTN):c.23363C>T (p.Ser7788Phe)SNV Likely benign 691754 2:179585126-179585126 2:178720399-178720399
17 ANK2 NM_001148.6(ANK2):c.4123-13T>CSNV Likely benign 347321 rs759465783 4:114264160-114264160 4:113343004-113343004
18 HCN4 NM_005477.3(HCN4):c.1243G>A (p.Val415Met)SNV Benign 412788 rs201978086 15:73624600-73624600 15:73332259-73332259

Expression for Congestive Heart Failure

Search GEO for disease gene expression data for Congestive Heart Failure.

Pathways for Congestive Heart Failure

Pathways related to Congestive Heart Failure according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 VCL TTN NPPC NPPA MYH6 CACNA1C
2
Show member pathways
12.37 VCL MYH7 MYH6 ACTN2
3
Show member pathways
12.26 NPPC NPPB NPPA EDN1 CACNA1C AGTR1
4
Show member pathways
12.11 NPPC NPPB NPPA MYH7 MYH6 CACNA1C
5 12.07 NPPA EDN1 CACNA1C ADRB1
6
Show member pathways
11.97 TTN MYH7 MYH6 EDN1 CACNA1C ADRB1
7 11.61 MYH7 MYH6 CACNA1C
8
Show member pathways
11.56 REN AGTR1 ACE
9 11.49 TTN MYH6 ACTN2
10 11.01 REN NPPA EDN1 CACNA1C AGTR1 ADRB1
11 10.98 CACNA1C ADRB1 ADRA2C ADM
12 10.92 NPPB NPPA MYH7

GO Terms for Congestive Heart Failure

Cellular components related to Congestive Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.1 VCL TTN REN NPPB NPPA MYH7
2 extracellular region GO:0005576 9.85 VCL TTN REN NPPC NPPB NPPA
3 muscle myosin complex GO:0005859 9.32 MYH7 MYH6
4 sarcomere GO:0030017 9.26 TTN MYH7 MYH6 ACTN2
5 Z disc GO:0030018 9.1 TTN MYH7 MYH6 CRYAB CACNA1C ACTN2

Biological processes related to Congestive Heart Failure according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.96 EDN1 CRYAB CDKN2B-AS1 ACE
2 protein folding GO:0006457 9.88 NPPC NPPB NPPA CRYAB
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.87 EDN1 CACNA1C AGTR1 ADM
4 response to hypoxia GO:0001666 9.83 NPPC NPPA EDN1 CRYAB ADM
5 female pregnancy GO:0007565 9.8 NPPA ADRA2C ADM
6 cardiac muscle contraction GO:0060048 9.75 TTN MYH7 MYH6
7 sarcomere organization GO:0045214 9.72 TTN MYH6 ACTN2
8 cGMP-mediated signaling GO:0019934 9.7 NPPC NPPB NPPA
9 positive regulation of heart rate GO:0010460 9.69 NPPA EDN1 ADM
10 regulation of blood vessel diameter GO:0097746 9.67 NPPB AGTR1 ACE
11 response to muscle stretch GO:0035994 9.65 NPPA EDN1
12 amyloid-beta metabolic process GO:0050435 9.65 REN ACE
13 regulation of the force of heart contraction GO:0002026 9.65 MYH7 MYH6 ADM
14 positive regulation of renal sodium excretion GO:0035815 9.64 NPPB EDN1
15 positive regulation of urine volume GO:0035810 9.64 NPPB EDN1
16 adult heart development GO:0007512 9.63 MYH7 MYH6
17 negative regulation of systemic arterial blood pressure GO:0003085 9.63 NPPB NPPA
18 striated muscle contraction GO:0006941 9.63 TTN MYH7 MYH6
19 cardiac muscle fiber development GO:0048739 9.62 TTN MYH6
20 angiotensin maturation GO:0002003 9.61 REN ACE
21 body fluid secretion GO:0007589 9.61 NPPB EDN1
22 positive regulation of cGMP-mediated signaling GO:0010753 9.6 NPPC NPPA
23 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.59 AGTR1 ACE
24 cardiac muscle hypertrophy in response to stress GO:0014898 9.58 NPPA MYH7 MYH6
25 renin-angiotensin regulation of aldosterone production GO:0002018 9.56 REN AGTR1
26 muscle filament sliding GO:0030049 9.56 TTN MYH7 MYH6 ACTN2
27 phospholipase C-activating angiotensin-activated signaling pathway GO:0086097 9.54 AGTR1 ACTN2
28 cGMP biosynthetic process GO:0006182 9.54 NPPC NPPB NPPA
29 receptor guanylyl cyclase signaling pathway GO:0007168 9.5 NPPC NPPB NPPA
30 regulation of vasoconstriction GO:0019229 9.46 EDN1 AGTR1 ADRA2C ACE
31 muscle contraction GO:0006936 9.43 VCL TTN MYH7 MYH6 CRYAB ACTN2
32 regulation of blood pressure GO:0008217 9.1 REN NPPB NPPA MYH6 EDN1 ACE

Molecular functions related to Congestive Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.71 TTN MYH7 MYH6 CACNA1C
2 actin filament binding GO:0051015 9.65 VCL TTN MYH7 MYH6 ACTN2
3 signaling receptor binding GO:0005102 9.63 REN NPPC NPPB NPPA EDN1 ADM
4 epinephrine binding GO:0051379 9.43 ADRB1 ADRA2C
5 alpha-2A adrenergic receptor binding GO:0031694 9.37 ADRB1 ADRA2C
6 hormone activity GO:0005179 9.35 NPPC NPPB NPPA EDN1 ADM
7 bradykinin receptor binding GO:0031711 9.32 AGTR1 ACE
8 hormone receptor binding GO:0051427 8.8 NPPC NPPB NPPA

Sources for Congestive Heart Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....